Moving EGFR Targeted Therapy into the Induction Phase of the Management of Squamous Cell Carcinoma of the Head and Neck

Authors

  • Belisario A. Arango Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center/University of Miami Miller School of Medicine, Miami, FL
  • Bertha E. Sanchez Department of Medicine, Henry Ford Hospital, Detroit, MI
  • Matthew C. Abramowitz Department of Radiation Therapy, Sylvester Comprehensive Cancer Center/University of Miami Miller School of Medicine, Miami, FL, USA
  • Edgardo S. Santos Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center/University of Miami Miller School of Medicine, Miami, FL

DOI:

https://doi.org/10.6000/1929-2279.2012.01.01.04

Keywords:

Cetuximab, chemoimmunotherapy, concurrent chemoradiation, epidermal growth factor receptor, head and neck cancer, Human papilloma virus, induction therapy, organ preservation, radiation therapy, sequential approach.

Abstract

 Many advances in the treatment of squamous cell carcinoma of the head and neck have occurred in the past few years. Since the advent of cetuximab, a chimeric monoclonal antibody against epidermal growth factor receptor, the search for other efficacious targeted therapies has awakened the interest and curiosity of researchers and clinicians. Initially, cetuximab demonstrated effectiveness as single agent in heavily pretreated patients diagnosed with head and neck cancer, and has demonstrated to improve locoregional control and survival when combined with radiotherapy. Thesuccess of cetuximab has transitioned to other settings and with different modalities such as in combination with other conventional cytotoxic agents in the metastatic setting, combined with radiation therapy as part of concurrent treatment, and lately, in combination with other agents in the induction phase of the sequential approach. In this review, we discuss all different modalities in combination with cetuximab and how cetuximab has been incorporated into other clinical settings with only one goal in mind: improve the survival rates of our patients.

References

Jemal A, Siegel R, Hao Y, Xu J, Ward E. Cancer statistics. Cancer J Clin 2009; 59: 225-9. http://dx.doi.org/10.3322/caac.20006

Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010; 116:544–73. http://dx.doi.org/10.1002/cncr.24760

American Cancer Society. Cancer facts and figures, 2010: Available from: http://www.cancer.org/docroot/STT/STT_0.asp. Accessed 20 December 2010.

Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 32: 4294-301. http://dx.doi.org/10.1200/JCO.2011.36.4596

Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Eng J Med 2010; 363: 24-35. http://dx.doi.org/10.1056/NEJMoa0912217

Fischer CA, Kampmann M, Zlobec I, et al. p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters. Ann Oncol 2010; 21: 1961-6. http://dx.doi.org/10.1093/annonc/mdq210

Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004; 22: 1743-52. http://dx.doi.org/10.1200/JCO.2004.06.147

Iro H, Waldfahrer F. Evaluation of the newly updated TNM classification of head and neck carcinoma with data from 3247 patients. Cancer 1998; 83: 2201-7. http://dx.doi.org/10.1002/(SICI)1097-0142(19981115)83:10<2201::AID-CNCR20>3.0.CO;2-7

Kowalski LP, Carvalho AL. Natural history of untreated head and neck cancer. Eur J Cancer 2000; 36: 1032-7. http://dx.doi.org/10.1016/S0959-8049(00)00054-X

Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000; 355: 949-55. http://dx.doi.org/10.1016/S0140-6736(00)90011-0

Pignon JP, le Maitre A, Bourhis J. Meta-Analyses of chemotherapy in head and neck cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007; 69(2 Suppl): S112-4. http://dx.doi.org/10.1016/j.ijrobp.2007.04.088

Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomized trials and 17 346 patients. Radiother Oncol 2009; 92: 4-14. http://dx.doi.org/10.1016/j.radonc.2009.04.014

Hitt R, López-Pousa A, Martínez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23: 8636-45. http://dx.doi.org/10.1200/JCO.2004.00.1990

Santini J, Formento JL, Francoual M, et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991; 13: 132-9. http://dx.doi.org/10.1002/hed.2880130209

Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11: 1873-88.

Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90(11): 824-32. http://dx.doi.org/10.1093/jnci/90.11.824

Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37: S9-S15. (Suppl 4).

Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62: 7350-6.

O-Charoenrat P, Rhys-Evans PH, Archer DJ, Eccles SA. C-erbB receptors in squamous cell carcinoma of the head and neck: Clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol 2002; 38: 73-80. http://dx.doi.org/10.1016/S1368-8375(01)00029-X

Urba S, Wolf G, Eisbruch A, et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm. J Clin Oncol 2006; 24: 593-8. http://dx.doi.org/10.1200/JCO.2005.01.2047

Forastiere AA. Long-term results of Intergroup RTOG 91-11: a phase III trial to preserve the larynx- induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. In: American Society of Clinical Oncology Annual Meeting Proceedings Part I. 2006; Vol. 24(18S): p. 5517a.

Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996; 88: 890-99. http://dx.doi.org/10.1093/jnci/88.13.890

Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-8. http://dx.doi.org/10.1056/NEJMoa031317

Lefebvre JL, Andry G, Chevalier D, et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squmous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol 2012 Apr 6.

The department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-90. http://dx.doi.org/10.1056/NEJM199106133242402

Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-704. http://dx.doi.org/10.1056/NEJMoa071028

Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705-15. http://dx.doi.org/10.1056/NEJMoa070956

Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311-8.

Hadari YR, Doody JF, Wang Y, et al. The IgG1 monoclonal antibody cetuximab induces degradation of the epidermal growth factor receptor. In: 2004 Gastrointestinal Cancers Symposium 2004: 234a.

Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78. http://dx.doi.org/10.1056/NEJMoa053422

Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11(1): 21-8. http://dx.doi.org/10.1016/S1470-2045(09)70311-0

Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007; 25: 2191-7. http://dx.doi.org/10.1200/JCO.2006.08.8005

Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994; 269: 27595-602.

Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor positive tumors: A new paradigm for cancer therapy. Cancer 2002; 94: 1593-611. http://dx.doi.org/10.1002/cncr.10372

Bourhis J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2866-72. http://dx.doi.org/10.1200/JCO.2005.04.3547

Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the anti epidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5568-77. http://dx.doi.org/10.1200/JCO.2005.07.119

Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-54. http://dx.doi.org/10.1200/JCO.2005.02.4646

Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5578-87. http://dx.doi.org/10.1200/JCO.2005.07.120

Vermoken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-27. http://dx.doi.org/10.1056/NEJMoa0802656

Mesía R, Rivera F, Kawecki A, et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 2010; 21(10): 1967-73. http://dx.doi.org/10.1093/annonc/mdq077

Licitra L, Mesia R, Rivera F, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol 2011; 22(5): 1078-87. http://dx.doi.org/10.1093/annonc/mdq588

Birnbaum A, Johnson TT, Rathore R, et al. Induction cetuximab (C) followed by C, paclitaxel (P), carboplatin (CP) and concurrent radiation (RT) for locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN). In: American Society of Clinical Oncology Annual Meeting Proceedings Part I. 2007; Vol. 25(18S): p. 16504a.

Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol 2010; 28: 8-14. http://dx.doi.org/10.1200/JCO.2009.23.0425

Wanebo HJ, Ghebremichael M, Burtness B, Spencer S, Ridge J, Forastiere A. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303). In: American Society of Clinical Oncology Annual Meeting Proceedings Part I. 2007; Vol 25(18S): p. 6015a.

Tsoutsou PG, Panteliadou M, Papadopoulou A, Abatzoglou I, Sismanidou K, Tsiarkatzi M. Neoadjuvant cisplatin (CDDP) chemotherapy (CT) with docetaxel (D) and cetuximab (Cmab) followed by concurrent radiochemotherapy (RTCT) in locally advanced head and neck cancer (LA-HNC). In: American Society of Clinical Oncology Annual Meeting Proceedings Part I. 2010; Vol. 28(15S): p. e16025.

Argiris AE, Gibson MK, Heron DE, Smith RP, Ferris RL, Laisy. Phase II trial of neoadjuvant docetaxel, cisplatin, and cetuximab followed by concurrent radiation, ciplastin, and cetuximab in locally advanced head and neck cancer. In: American Society of Clinical Oncology Annual Meeting Proceedings Part I. 2008; Vol. 26(20S): p. 6002a.

Haddad RI, Tishler RB, Norris C, et al. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27(27): 4448-53. http://dx.doi.org/10.1200/JCO.2009.22.1333

Adkins D, Ley J, Nussenbaum B, Diaz J, Paniello R, Thorstad WL. Clinical response rate at primary tumor site (PTS) following a novel induction chemotherapy (IC) regimen of weekly nanoparticle albumin-bound (nab-) paclitaxel and cetuximab with every-3-week cisplatin and 5-FU (ACCF) versus docetaxel, cisplatin, 5-FU, and cetuximab (TPF + C) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2011; 29(15S): 5560a.

Kuperman DI, Ley J, Nussenbaum B, Diaz J, Paniello R, Thorstad WL. Safety analysis of a novel induction chemotherapy (IC) regiman of weekly nanoparticle albumin-bound (nab-) paclitaxel and cetuximab with every 3 week cisplatin and 5-FU in 30 patients (pts) with locally advanced nonmetastatic head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2011; 29(15S): e16025.

Kuperman DI, Nussenbaum B, Thorstad W, Haughey B, Lewis J, Adkins D. Retrospective analysis of the addition of cetuximab to induction chemotherapy (IC) with docetaxel, cisplatin, and 5-fluorouracil (TPF-C) for locally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) J Clin Oncol 2007; 25(18S): 6072a.

Downloads

Published

2012-01-28

How to Cite

Belisario A. Arango, Bertha E. Sanchez, Matthew C. Abramowitz, & Edgardo S. Santos. (2012). Moving EGFR Targeted Therapy into the Induction Phase of the Management of Squamous Cell Carcinoma of the Head and Neck . Journal of Cancer Research Updates, 1(1),  14–21. https://doi.org/10.6000/1929-2279.2012.01.01.04

Issue

Section

Articles

Similar Articles

You may also start an advanced similarity search for this article.